Patent highlights December 2022-January 2023.

Pharmaceutical Patent AnalystAhead of Print Patent HighlightsPatent highlights December 2022–January 2023Hermann AM MuckeHermann AM Mucke *Author for correspondence: E-mail Address: h.mucke@hmpharmacon.comhttps://orcid.org/0000-0002-1491-6250H.M. Pharma Consultancy, A-1160, Wien, AustriaSearch for more papers by this authorPublished Online:6 Oct 2023https://doi.org/10.4155/ppa-2023-0016AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34(4), 985–1005 (2020).Crossref, Medline, Google Scholar2. Kang C. Teclistamab: First Approval. Drugs 82(16), 1613–1619 (2022).Crossref, Medline, CAS, Google Scholar3. Martens AWJ, Rietveld JM, de Boer R et al. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Res. Commun. 2(5), 330–341 (2022).Crossref, Medline, CAS, Google Scholar4. Yago H, Fujita Y, Kaku H et al. Study on pruritus in hemodialysis patients and the antipruritic effect of neurotropin: plasma levels of C3a, C5a, bradykinin and lipid peroxides. Nihon Jinzo Gakkai Shi. 31(10), 1061–1067 (1989).Medline, CAS, Google Scholar5. Kapp A, Wokalek H, Schöpf E. Involvement of complement in psoriasis and atopic dermatitis – Measurement of C3a and C5a, C3, C4 and C1 inactivator. Arch. Dermatol. Res. 277(5), 359–361 (1985).Crossref, Medline, CAS, Google Scholar6. Reid RC, Yau M-K, Singh R et al. Potent Heterocyclic Ligands for Human Complement C3a Receptor. J. Med. Chem. 57(20), 8459–8470 (2014).Crossref, Medline, CAS, Google Scholar7. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184(10), 2537–2564 (2021).Crossref, Medline, CAS, Google Scholar8. Gutierrez AH, Mazariegos MS, Alemany S, Nevzorova YA, Cubero FJ, Sanz-García C. Tumor progression locus 2 (TPL2): a Cot-plicated progression from inflammation to chronic liver disease. Biochim. Biophys Acta BBA – Mol. Basis Dis. 1869(4), 166660 (2023).Crossref, Medline, CAS, Google Scholar9. Kim C-W, Addy C, Kusunoki J et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab. 26(2), 394–406; e6 (2017).Crossref, Medline, CAS, Google Scholar10. Jia C-E, Jiang D, Dai H, Xiao F, Wang C. Pendrin, an anion exchanger on lung epithelial cells, could be a novel target for lipopolysaccharide-induced acute lung injury mice. Am. J. Transl. Res. 8(2), 981–992 (2016).Medline, CAS, Google Scholar11. Nofziger C, Dossena S, Suzuki S, Izuhara K, Paulmichl M. Pendrin Function in Airway Epithelia. Cell Physiol. Biochem. 28(3), 571–578 (2011).Crossref, Medline, CAS, Google Scholar12. Park J, Lee HJ, Song D et al. Novel pendrin inhibitor attenuates airway hyperresponsiveness and mucin expression in experimental murine asthma. J. Allergy Clin. Immunol. 144(5), 1425–1428; e12 (2019).Crossref, Medline, Google Scholar13. Lee EH, Shin MH, Gi M et al. Inhibition of Pendrin by a small molecule reduces Lipopolysaccharide-induced acute Lung Injury. Theranostics 10(22), 9913–9922 (2020).Crossref, Medline, CAS, Google Scholar14. Bao C, Bajrami B, Marcotte DJ et al. Mechanisms of Regulation and Diverse Activities of Tau-Tubulin Kinase (TTBK) Isoforms. Cell. Mol. Neurobiol. 41(4), 669–685 (2021).Crossref, Medline, CAS, Google Scholar15. Nozal V, Martinez A. Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. Eur. J. Med. Chem. 161, 39–47 (2019).Crossref, Medline, CAS, Google Scholar16. Gevaert AB, Kataria R, Zannad F et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart 108(17), 1342–1350 (2022).Crossref, Medline, Google Scholar17. Briand F, Maupoint J, Brousseau E et al. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Metab. – Clin. Exp. 117, 154707 (2021).Crossref, Medline, CAS, Google Scholar18. Bódi B, Kovács Á, Gulyás H et al. Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts. Antioxidants 10(11), 1776 (2021).Crossref, Medline, CAS, Google Scholar19. Pramanik J, Chen X, Kar G et al. Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation. Genome Med. 10(1), 76 (2018).Crossref, Medline, CAS, Google Scholar20. Li X, Zhu H, Huang H et al. Study on the effect of IRE1α on cell growth and apoptosis via modulation PLK1 in ER stress response. Mol. Cell. Biochem. 365(1), 99–108 (2012).Crossref, Medline, CAS, Google Scholar21. Schlesinger N, Padnick-Silver L, LaMoreaux B. Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. BioDrugs 36(2), 95–103 (2022).Crossref, Medline, CAS, Google Scholar22. Luperchio TR, Kozel BA. Extending the spectrum in aortopathy: stenosis to aneurysm. Curr. Opin. Genet. Dev. 76, 101962 (2022).Crossref, Medline, CAS, Google Scholar23. Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc. Res. 118(2), 372–385 (2022).Crossref, Medline, CAS, Google Scholar24. Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem. Sci. 42(4), 245–254 (2017).Crossref, Medline, CAS, Google Scholar25. Hu JJ, Liu X, Xia S et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat. Immunol. 21(7), 736–745 (2020).Crossref, Medline, CAS, Google Scholar26. Rathkey JK, Zhao J, Liu Z et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci. Immunol. 3(26), eaat2738 (2018).Crossref, Medline, Google Scholar27. Yun J, Finkel T. Mitohormesis. Cell Metab. 19(5), 757–766 (2014).Crossref, Medline, CAS, Google Scholar28. Proudfoot D. Calcium Signaling and Tissue Calcification. Cold Spring Harb. Perspect. Biol. 11(10), a035303 (2019).Crossref, Medline, CAS, Google Scholar29. Brosnan ME, Brosnan JT. Histidine Metabolism and Function. J. Nutr. 150, S2570–S2575 (2020).Crossref, Google Scholar30. Luu N, Fu L, Fujimoto K, Shi Y-B. Direct Regulation of Histidine Ammonia-Lyase 2 Gene by Thyroid Hormone in the Developing Adult Intestinal Stem Cells. Endocrinology 158(4), 1022–1033 (2017).Crossref, Medline, CAS, Google Scholar31. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4(3), 202–213 (2003).Crossref, Medline, CAS, Google Scholar32. Ali LMA, Simon M, El Cheikh K et al. Topological Requirements for CI-M6PR-Mediated Cell Uptake. Bioconjug. Chem. 30(10), 2533–2538 (2019).Crossref, Medline, CAS, Google Scholar33. Wang Z-J, Levinson S, Sun L, Heinbockel T. Identification of both GABAA receptors and voltage-activated Na+ channels as molecular targets of anticonvulsant α-asarone. Front Pharmacol. 5, 40 (2014).Crossref, Medline, Google Scholar34. Balakrishnan R, Cho D-Y, Kim I-S, Seol S-H, Choi D-K. Molecular Mechanisms and Therapeutic Potential of α- and β-Asarone in the Treatment of Neurological Disorders. Antioxidants 11(2), 281 (2022).Crossref, Medline, CAS, Google Scholar35. Uebel T, Hermes L, Haupenthal S, Müller L, Esselen M. α-Asarone, β-asarone, and γ-asarone: current status of toxicological evaluation. J. Appl. Toxicol. 41(8), 1166–1179 (2021).Crossref, Medline, CAS, Google Scholar36. Varelas P, Jones M. Antiepileptic Drugs in the Neurosurgical Intensive Care. Curr. Pharm. Des. 23(42), 6533–6550 (2017).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Published online 6 October 2023 Information© 2023 Newlands PressFinancial disclosureThe authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download